The significant reduction in the blood glucose levels in DEX rats by treatment with a glucagon receptor antagonist points to the crucial involvement of glucagon in the diabetogenic effects of GCs and also indicates the antagonism of the glucagon receptor as a potential therapeutic target to ameliorate the hyperglycemia resulting from GC therapy. This evidence concerns the gene GCGR and Hyperglycemia.